Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Common Equity: 2020-2025

Historic Common Equity for Mereo BioPharma Group (MREO) over the last 2 years, with Sep 2025 value amounting to $46.6 million.

  • Mereo BioPharma Group's Common Equity fell 35.76% to $46.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.6 million, marking a year-over-year decrease of 35.76%. This contributed to the annual value of $61.0 million for FY2024, which is 20.64% up from last year.
  • Per Mereo BioPharma Group's latest filing, its Common Equity stood at $46.6 million for Q3 2025, which was down 13.99% from $54.2 million recorded in Q2 2025.
  • Mereo BioPharma Group's Common Equity's 5-year high stood at $118.6 million during Q4 2021, with a 5-year trough of -$24,126 in Q2 2022.
  • Over the past 3 years, Mereo BioPharma Group's median Common Equity value was $57.1 million (recorded in 2025), while the average stood at $58.3 million.
  • In the last 5 years, Mereo BioPharma Group's Common Equity soared by 700.08% in 2021 and then plummeted by 242.79% in 2022.
  • Quarterly analysis of 5 years shows Mereo BioPharma Group's Common Equity stood at $118.6 million in 2021, then slumped by 56.67% to $51.4 million in 2022, then declined by 1.68% to $50.5 million in 2023, then climbed by 20.64% to $61.0 million in 2024, then crashed by 35.76% to $46.6 million in 2025.
  • Its Common Equity stands at $46.6 million for Q3 2025, versus $54.2 million for Q2 2025 and $60.1 million for Q1 2025.